Recent research have focused on the convergence of glucagon-like peptide-1|glucose-dependent insulinotropic polypeptide|glucagon receptor activator therapies and dopamine neurotransmission. While GIP activators are widely employed for treating type 2 T2DM, their emerging consequences on motivation circuits, specifically mediated by dopamine systems